Citius Pharmaceuticals, Inc.

Submit an IND and initiate Phase 1 study for i-MSCs

Deadline passed; outcome being checked

Announced: 16 Feb 2021
Due: 30 Jun 2022
Status: Checking

Deadline
Met
Late
Not met
Today

What the company said

“We plan to submit an IND to the FDA and initiate our Phase 1 study by the end of the second quarter of 2022.”

SourceCitius Pharmaceuticals, Inc. Form 8-K press release, 2021-02-16
FilingSEC filing index
Deadline as statedby the end of the second quarter of 2022
Deadline used30 Jun 2022, the last day of the stated period
TypeRegulatory
Permanent referenceKI-C-2021-CTXR-023867
Cite as https://keptindex.org/c/KI-C-2021-CTXR-023867/ — this address never changes.

What we found

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Regulatory filing
Indicative materiality: Medium rules
Action: Submit
Deliverable: i-MSC IND and Phase 1 study
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High
Depends on: Regulatory

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Citius Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-CTXR-023867 · Corrections policy